Skip to content

IgD Mab Technology (IMT)

IMT is a private Australian biotechnology startup company based in Sydney Australia that focuses on the clinical & commercial development of therapeutic anti-IgD monoclonal antibody (mAb) as a first-in-class disease-modifying mAb drug for human autoimmune diseases, allergic conditions and B-CLL.

  • Home
  • About IMT
  • Research Publications
  • News & Updates
  • Investment & Partnership Opportunity
  • Contact

Projects

Anti-IgD monoclonal as novel treatment for human autoimmune diseases and pro-inflammatory conditions.

Share this:

  • Click to share on X (Opens in new window) X
  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Click to share on WhatsApp (Opens in new window) WhatsApp
  • Click to share on LinkedIn (Opens in new window) LinkedIn
Like Loading...

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 3 other subscribers
  • Home
  • About IMT
  • Research Publications
  • News & Updates
  • Investment & Partnership Opportunity
  • Contact
IgD Mab Technology (IMT) Blog at WordPress.com.
  • Subscribe Subscribed
    • IgD Mab Technology (IMT)
    • Already have a WordPress.com account? Log in now.
    • IgD Mab Technology (IMT)
    • Subscribe Subscribed
    • Sign up
    • Log in
    • Copy shortlink
    • Report this content
    • View post in Reader
    • Manage subscriptions
    • Collapse this bar
%d